(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.
The three biggest winners today are BENEVOLENTAI, PARROT, and ADOCIA.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| BENEVOLENTAI (BAI.AS) | 1.17 | 46.25% | 2023-12-27 12:00:54 |
| PARROT (PARRO.PA) | 2.64 | 21.66% | 2023-12-27 13:21:10 |
| ADOCIA (ADOC.PA) | 11.90 | 15.98% | 2023-12-27 12:44:53 |
| BERGENBIO (BGBIO.OL) | 0.28 | 14.61% | 2023-12-27 12:25:05 |
| HDF (HDF.PA) | 12.32 | 12.41% | 2023-12-27 13:04:40 |
| CASINO GUICHARD (CO.PA) | 0.79 | 11.97% | 2023-12-27 13:00:53 |
| HYLORIS (HYL.BR) | 12.80 | 10.34% | 2023-12-27 12:20:10 |
| DBV TECHNOLOGIES (DBV.PA) | 1.97 | 10.17% | 2023-12-27 13:02:03 |
| FOUNTAIN (FOU.BR) | 1.22 | 8.93% | 2023-12-27 12:06:11 |
| ALUMEXX N.V. (ALX.AS) | 1.03 | 8.42% | 2023-12-27 12:00:26 |
The three biggest losers today are AFFLUENT MEDICAL, FUT.CLUBE PORTO, and MKB Nedsense.
| Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|
| AFFLUENT MEDICAL (AFME.PA) | 1.90 | -17.25% | 2023-12-27 12:45:05 |
| FUT.CLUBE PORTO (FCP.LS) | 1.16 | -7.94% | 2023-12-27 12:23:16 |
| MKB Nedsense (NEDSE.AS) | 0.09 | -7.54% | 2023-12-27 12:02:51 |
| EASE2PAY NV (EAS2P.AS) | 0.60 | -5.66% | 2023-12-27 12:01:39 |
| MPC CONTAINER SHIP (MPCC.OL) | 13.52 | -5.36% | 2023-12-27 12:41:11 |
| GLINTT (GLINT.LS) | 0.36 | -5.26% | 2023-12-27 12:23:20 |
| SHOWROOMPRIVE (SRP.PA) | 0.95 | -5.19% | 2023-12-27 13:22:41 |
| FRONTLINE (FRO.OL) | 207.25 | -5.08% | 2023-12-27 12:26:09 |
| EQVA (EQVA.OL) | 3.08 | -4.94% | 2023-12-27 12:26:04 |
| IEX GROUP NV (IEX.AS) | 1.75 | -4.89% | 2023-12-27 12:02:30 |
Winners today
1. BENEVOLENTAI (BAI.AS)
46.25% Price Change
BenevolentAI S.A. operates as a clinical-stage AI-enabled drug discovery and development company. Its BenevolentAI platform powers in-house drug pipeline of drug programs. The company's therapeutic areas, include atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis, glioblastoma multiforme, inflammatory bowel disease, antiviral, oncology, parkinson's disease, nonalcoholic steatohepatitis, fibrosis, inflammation, chronic kidney disease, and idiopathic pulmonary fibrosis. It has a collaboration with AstraZeneca to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.
AEX-Index ended the session with BENEVOLENTAI rising 46.25% to €1.17 on Wednesday, after two consecutive sessions in a row of gains. AEX-Index jumped 0.18% to €786.84, after two successive sessions in a row of losses, on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, BENEVOLENTAI has a trailing twelve months EPS of €-0.47.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.97%.
More news about BENEVOLENTAI.
2. PARROT (PARRO.PA)
21.66% Price Change
Parrot S.A. provides professional drones and software and services in France and internationally. The company also offers Open Flight, an open-source core of FreeFlight 7 app for ANAFI Ai; Air SDK, a development software kit for autonomous drones; Ground SDK, a ground control station framework for mobile device; Developer Forum, an open-source development platform; and Sphinx, a 3D photorealistic drone simulation tool. In addition, it offers C.A.D. modeling used for accessories 3D printing or additive manufacturing; Olympe provides a Python controller programming interface for ANAFI Ai; and PDrAW, an advanced video viewer for ANAFI Ai media. The company offers its products for inspection, first responders, firefighters, search-and-rescue teams, security agencies, and surveying professionals. Parrot S.A. was incorporated in 1994 and is headquartered in Paris, France.
CAC 40 ended the session with PARROT rising 21.66% to €2.64 on Wednesday, following the last session’s upward trend. CAC 40 rose 0.04% to €7,571.82, after two sequential sessions in a row of losses, on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, PARROT has a trailing twelve months EPS of €-0.91.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.52%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PARROT’s stock is considered to be oversold (<=20).
Revenue Growth
Year-on-year quarterly revenue growth grew by 3.3%, now sitting on 72.97M for the twelve trailing months.
More news about PARROT.
3. ADOCIA (ADOC.PA)
15.98% Price Change
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
CAC 40 ended the session with ADOCIA rising 15.98% to €11.90 on Wednesday while CAC 40 jumped 0.04% to €7,571.82.
Earnings Per Share
As for profitability, ADOCIA has a trailing twelve months EPS of €-2.5.
Moving Average
ADOCIA’s worth is way higher than its 50-day moving average of €7.88 and way higher than its 200-day moving average of €5.76.
Volume
Today’s last reported volume for ADOCIA is 363923 which is 103.38% above its average volume of 178937.
More news about ADOCIA.
4. BERGENBIO (BGBIO.OL)
14.61% Price Change
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Oslo Børs Benchmark Index_GI ended the session with BERGENBIO rising 14.61% to €0.28 on Wednesday, after four sequential sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.9% to €1,307.10, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, BERGENBIO has a trailing twelve months EPS of kr-0.55.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -179.58%.
More news about BERGENBIO.
5. HDF (HDF.PA)
12.41% Price Change
Hydrogène de France Société anonyme develops and operates as independent power producer in France and internationally. It operates two hydrogen power plants; and manufactures and sells high power fuel cells. The company was incorporated in 2012 and is based in Lormont, France.
CAC 40 ended the session with HDF rising 12.41% to €12.32 on Wednesday while CAC 40 jumped 0.04% to €7,571.82.
Earnings Per Share
As for profitability, HDF has a trailing twelve months EPS of €-0.24.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.11%.
More news about HDF.
6. CASINO GUICHARD (CO.PA)
11.97% Price Change
Casino, Guichard-Perrachon S.A. operates as a food retailer in France, Latin America, and internationally. The company operates hypermarkets, supermarkets, shopping malls, and e-commerce sites, as well as convenience, discount, and cash and carry stores. It also involved in banking, digital marketing, service station, franchise, real estate asset management, property development and trading, rental, banking, and energy-related activities. It operates through stores. The company was founded in 1898 and is based in Saint-Étienne, France.Casino, Guichard-Perrachon S.A operates as a subsidiary of Rallye SA.
CAC 40 ended the session with CASINO GUICHARD jumping 11.97% to €0.79 on Wednesday while CAC 40 rose 0.04% to €7,571.82.
Earnings Per Share
As for profitability, CASINO GUICHARD has a trailing twelve months EPS of €-20.53.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -65.71%.
More news about CASINO GUICHARD.
7. HYLORIS (HYL.BR)
10.34% Price Change
Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas. It offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. The company provides Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative non-opioid pain management; Tranexamic acid RTU, an antifibrinolytic drug for the formation of blood clots; Miconazole/Domiphen Bromide, a topical synergistic combination treatment for Recurrent Vulvovaginal Candidiasis; AlenuraTM, a first-line drug treatment for acute pain in interstitial cystitis/bladder pain syndrome; and Plecoid Agent IV for the treatment of acute myeloid leukemia and small cell lung cancer. It also offers Atomoxetine, an oral liquid for the treatment of patients with attention deficit hyperactivity disorder; HY-029, a liquid formulation of an antiviral drug to treat viral infections; HY-083, a nasal spray for the treatment of idiopathic rhinitis; and HY-088, an oral liquid that treats hypophosphatemia. The company was incorporated in 2012 and is headquartered in Liège, Belgium.
BEL 20 ended the session with HYLORIS jumping 10.34% to €12.80 on Wednesday while BEL 20 jumped 0.85% to €3,711.12.
Earnings Per Share
As for profitability, HYLORIS has a trailing twelve months EPS of €-0.46.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.8%.
More news about HYLORIS.
8. DBV TECHNOLOGIES (DBV.PA)
10.17% Price Change
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
CAC 40 ended the session with DBV TECHNOLOGIES rising 10.17% to €1.97 on Wednesday while CAC 40 jumped 0.04% to €7,571.82.
Earnings Per Share
As for profitability, DBV TECHNOLOGIES has a trailing twelve months EPS of €-1.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -56.61%.
Volatility
DBV TECHNOLOGIES’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.91%, a positive 0.89%, and a positive 2.46%.
DBV TECHNOLOGIES’s highest amplitude of average volatility was 1.91% (last week), 2.79% (last month), and 2.46% (last quarter).
More news about DBV TECHNOLOGIES.
9. FOUNTAIN (FOU.BR)
8.93% Price Change
Fountain S.A. engages in the sale, rental, and provision of machines for cold and hot drinks made from freeze-dried or grain products in in France, Belgium, the Netherlands, and rest of European Countries. It provides coffee and cartridge machines, and other beverages machines. The company offers its products through independent distributors. Fountain S.A. was incorporated in 1972 and is based in Braine l'Alleud, Belgium.
BEL 20 ended the session with FOUNTAIN rising 8.93% to €1.22 on Wednesday while BEL 20 jumped 0.85% to €3,711.12.
Earnings Per Share
As for profitability, FOUNTAIN has a trailing twelve months EPS of €-0.11.
Volume
Today’s last reported volume for FOUNTAIN is 14 which is 99.33% below its average volume of 2099.
More news about FOUNTAIN.
10. ALUMEXX N.V. (ALX.AS)
8.42% Price Change
Alumexx N.V. manufactures and sells scaffoldings, stairs, ladders, accessories, and tools for indoor or outdoor use in the Netherlands and internationally. The company was formerly known as Phelix N.V. and changed its name to Alumexx N.V. in January 2018. Alumexx N.V. was founded in 1991 and is based in Etten-Leur, the Netherlands.
AEX-Index ended the session with ALUMEXX N.V. rising 8.42% to €1.03 on Wednesday while AEX-Index jumped 0.18% to €786.84.
Earnings Per Share
As for profitability, ALUMEXX N.V. has a trailing twelve months EPS of €0.12.
PE Ratio
ALUMEXX N.V. has a trailing twelve months price to earnings ratio of 8.58. Meaning, the purchaser of the share is investing €8.58 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 42.26%.
More news about ALUMEXX N.V..
Losers Today
1. AFFLUENT MEDICAL (AFME.PA)
-17.25% Price Change
Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.
CAC 40 ended the session with AFFLUENT MEDICAL falling 17.25% to €1.90 on Wednesday, after five successive sessions in a row of gains. CAC 40 jumped 0.04% to €7,571.82, after two sequential sessions in a row of losses, on what was a somewhat bullish trend exchanging session today.
Earnings Per Share
As for profitability, AFFLUENT MEDICAL has a trailing twelve months EPS of €-0.65.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.36%.
More news about AFFLUENT MEDICAL.
2. FUT.CLUBE PORTO (FCP.LS)
-7.94% Price Change
Futebol Clube do Porto – Futebol, S.A.D., together with its subsidiaries, participates in professional football competitions, and the sporting events promotion and organization in Portugal. It also engages in the image rights commercialization, sponsoring, merchandising, and products licensing activities; production, editing, and commercialization of multimedia material, as well as Internet, periodical, and non-periodical publications; and sport equipment management and exploration business, as well as insurance broking activities. In addition, the company organizes and sells travel and tour packages; and tickets and seat reservations, as well as represents travel agencies and tourism. Further, it is involved in the concept, design, development, production, direction, promotion, marketing, acquisition, exploration rights, recording, distribution, and dissemination of works and audiovisual programs, multimedia, television, video, cinema, theme, Internet, channels, tourist events, and cultural and sporting in any formats and systems. Additionally, the company manages, operates, and provides services in the areas of recording, production, and communication of audiovisual works, television shows, sounds, images, and other audiovisuals; and edits periodic publicities, books, and multimedia. It also explores for the Porto Canal cable television channel; and produces and executes advertisings, news reports, documentaries, and TV programs in video support. The company was founded in 1893 and is headquartered in Porto, Portugal.
PSI ended the session with FUT.CLUBE PORTO dropping 7.94% to €1.16 on Wednesday while PSI rose 0.04% to €6,424.52.
Earnings Per Share
As for profitability, FUT.CLUBE PORTO has a trailing twelve months EPS of €0.94.
PE Ratio
FUT.CLUBE PORTO has a trailing twelve months price to earnings ratio of 1.23. Meaning, the purchaser of the share is investing €1.23 for every euro of annual earnings.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FUT.CLUBE PORTO’s stock is considered to be oversold (<=20).
Volume
Today’s last reported volume for FUT.CLUBE PORTO is 57 which is 78.81% below its average volume of 269.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.3%, now sitting on 155.82M for the twelve trailing months.
More news about FUT.CLUBE PORTO.
3. MKB Nedsense (NEDSE.AS)
-7.54% Price Change
MKB Nedsense N.V. engages in the finance and lending of money to natural persons and legal entities. It also provides guarantees and/or other securities towards third parties for its obligations and/or for obligations for companies in the investment portfolio. The company was formerly known as Nedsense Enterprises N.V. MKB Nedsense N.V. was founded in 1999 and is based in Bussum, the Netherlands.
AEX-Index ended the session with MKB Nedsense dropping 7.54% to €0.09 on Wednesday while AEX-Index jumped 0.18% to €786.84.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.08%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 91.1%, now sitting on -50k for the twelve trailing months.
Moving Average
MKB Nedsense’s value is way under its 50-day moving average of €0.10 and way below its 200-day moving average of €0.11.
Yearly Top and Bottom Value
MKB Nedsense’s stock is valued at €0.09 at 21:40 EST, way below its 52-week high of €0.14 and above its 52-week low of €0.09.
Volume
Today’s last reported volume for MKB Nedsense is 94283 which is 733.99% above its average volume of 11305.
More news about MKB Nedsense.
4. EASE2PAY NV (EAS2P.AS)
-5.66% Price Change
Ease2pay N.V. provides online payment services and platforms in the Netherlands. The company operates payment transaction platform, which offers users services to order and pay in one action; and parking solutions. It also operates a platform that connects travelers with providers of parking and charging facilities on the road and water. The company was formerly known as DOCDATA N.V. and changed its name to Ease2pay N.V. in February 2018. Ease2pay N.V. is based in Rotterdam, the Netherlands.
AEX-Index ended the session with EASE2PAY NV sliding 5.66% to €0.60 on Wednesday while AEX-Index jumped 0.18% to €786.84.
Earnings Per Share
As for profitability, EASE2PAY NV has a trailing twelve months EPS of €-1.15.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -127.61%.
More news about EASE2PAY NV.
5. MPC CONTAINER SHIP (MPCC.OL)
-5.36% Price Change
MPC Container Ships ASA owns and operates a portfolio of container vessels. The company focuses on small-to mid-size vessels that are chartered out on time-charter contracts to global and regional liner shipping companies serving intra-regional trade lanes. It operates a fleet of 62 vessels with an aggregate capacity of approximately 134,270 twenty-foot equivalent units. MPC Container Ships ASA was incorporated in 2017 and is based in Oslo, Norway.
Oslo Børs Benchmark Index_GI ended the session with MPC CONTAINER SHIP falling 5.36% to €13.52 on Wednesday while Oslo Børs Benchmark Index_GI rose 0.9% to €1,307.10.
Earnings Per Share
As for profitability, MPC CONTAINER SHIP has a trailing twelve months EPS of kr9.11.
PE Ratio
MPC CONTAINER SHIP has a trailing twelve months price to earnings ratio of 1.48. Meaning, the purchaser of the share is investing kr1.48 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 52.99%.
More news about MPC CONTAINER SHIP.
6. GLINTT (GLINT.LS)
-5.26% Price Change
Glintt – Global Intelligent Technologies, S.A. provides IT consulting services for banking, insurance, public administration, and utilities sectors in Portugal, Spain, and Angola. It operates through two segments: Health and Other Markets. The company engages in the sale of equipment, furniture, consumables, and robotics solutions; development of architectural projects; and design and conception of lay-out and image for pharmacies, training, equipment maintenance, and consultancy projects. It licenses proprietary software solutions for healthcare providers, such as clinics, hospitals, pharmacies, and other bodies of the ministry of health; and develops, implements, and maintains software services for the health sector. In addition, the company implements ERPs, integrates internet systems, and develops tailor-made applications services. Further, the company develops, implements, and integrates partner platforms with emphasis on the BPM, ERP, BI and mobility solutions; and integrates IT infrastructures, as well as support for networking, security, storage systems, and database management. Glintt – Global Intelligent Technologies, S.A. was incorporated in 1995 and is based in Sintra, Portugal. Glintt – Global Intelligent Technologies, S.A. operates as a subsidiary of Farminveste – Investimentos, Participações E Gestão S.A.
PSI ended the session with GLINTT sliding 5.26% to €0.36 on Wednesday while PSI jumped 0.04% to €6,424.52.
Earnings Per Share
As for profitability, GLINTT has a trailing twelve months EPS of €0.04.
PE Ratio
GLINTT has a trailing twelve months price to earnings ratio of 9. Meaning, the purchaser of the share is investing €9 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.84%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.4%, now sitting on 115.18M for the twelve trailing months.
Moving Average
GLINTT’s worth is way above its 50-day moving average of €0.28 and way above its 200-day moving average of €0.25.
Volume
Today’s last reported volume for GLINTT is 1400 which is 88.9% below its average volume of 12616.
More news about GLINTT.
7. SHOWROOMPRIVE (SRP.PA)
-5.19% Price Change
SRP Groupe S.A. engages in the e-commerce business in France and internationally. The company operates Showroomprive.com, an online sales event site specialized in fashion; Beautéprivée, an online beauty sales event site; and Saldiprivati, a fashion site specializing in sales events. It also offers media advertising and logistics advisory services; develops and creates content optimized for e-commerce; operates a marketplace to assist retailers who want to sell their products directly; and supports brands in promoting and enhancing their CSR commitments. In addition, the company offers sport, maternity, work, and cocooning wear for women under the Collection IRL brand. The company was founded in 2006 and is headquartered in Saint-Denis, France.
CAC 40 ended the session with SHOWROOMPRIVE sliding 5.19% to €0.95 on Wednesday while CAC 40 rose 0.04% to €7,571.82.
Earnings Per Share
As for profitability, SHOWROOMPRIVE has a trailing twelve months EPS of €-0.03.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1.96%.
Yearly Top and Bottom Value
SHOWROOMPRIVE’s stock is valued at €0.95 at 21:40 EST, below its 52-week low of €0.98.
Moving Average
SHOWROOMPRIVE’s worth is under its 50-day moving average of €1.03 and way under its 200-day moving average of €1.27.
Sales Growth
SHOWROOMPRIVE’s sales growth for the next quarter is 2%.
Volatility
SHOWROOMPRIVE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.39%, a positive 0.01%, and a positive 1.33%.
SHOWROOMPRIVE’s highest amplitude of average volatility was 1.39% (last week), 1.64% (last month), and 1.33% (last quarter).
More news about SHOWROOMPRIVE.
8. FRONTLINE (FRO.OL)
-5.08% Price Change
Frontline plc, a shipping company, engages in the seaborne transportation of crude oil and oil products worldwide. It owns and operates oil and product tankers. As of December 31, 2022, the company operated a fleet of 70 vessels. It is also involved in the charter, purchase, and sale of vessels. The company was founded in 1985 and is based in Limassol, Cyprus.
Oslo Børs Benchmark Index_GI ended the session with FRONTLINE dropping 5.08% to €207.25 on Wednesday while Oslo Børs Benchmark Index_GI jumped 0.9% to €1,307.10.
Earnings Per Share
As for profitability, FRONTLINE has a trailing twelve months EPS of kr36.42.
PE Ratio
FRONTLINE has a trailing twelve months price to earnings ratio of 5.69. Meaning, the purchaser of the share is investing kr5.69 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.1%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 15, 2023, the estimated forward annual dividend rate is 20.26 and the estimated forward annual dividend yield is 10.59%.
More news about FRONTLINE.
9. EQVA (EQVA.OL)
-4.94% Price Change
Eqva ASA, a knowledge-based maritime company, primarily engages in the shipbuilding business worldwide. It operates in two segments, Shipbuilding Technology and Other. The company provides newbuilding, rebuilding, and service assignments on vessels for offshore oil production, renewable energy production, fishing, and fish farming for ship owners. It delivers technology for customers within the seafood, energy, and transport sectors. The company was formerly known as Havyard Group ASA and changed its name to Eqva ASA in November 2022. Eqva ASA was founded in 1999 and is headquartered in Fosnavåg, Norway.
Oslo Børs Benchmark Index_GI ended the session with EQVA falling 4.94% to €3.08 on Wednesday while Oslo Børs Benchmark Index_GI jumped 0.9% to €1,307.10.
Earnings Per Share
As for profitability, EQVA has a trailing twelve months EPS of kr-0.32.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.45%.
Volume
Today’s last reported volume for EQVA is 31459 which is 25.57% below its average volume of 42270.
More news about EQVA.
10. IEX GROUP NV (IEX.AS)
-4.89% Price Change
IEX Group N.V., through its subsidiaries, operates financial websites in the Netherlands and Belgium. It operates Beurs.nl, Belegger.nl, Beleggen.nl, DeBeurs.nl, Beursonline.nl, Participaties.nl, Beursgorilla.nl, Tostrams.nl and Guruwatch websites. The company also provides investment information services. In addition, the company offers IEX Expert and IEX Profs magazine for various investors; and organizes various events for private individuals and professionals. IEX Group N.V. was founded in 1999 and is based in Amsterdam, the Netherlands.
AEX-Index ended the session with IEX GROUP NV falling 4.89% to €1.75 on Wednesday while AEX-Index rose 0.18% to €786.84.
Earnings Per Share
As for profitability, IEX GROUP NV has a trailing twelve months EPS of €0.25.
PE Ratio
IEX GROUP NV has a trailing twelve months price to earnings ratio of 7. Meaning, the purchaser of the share is investing €7 for every euro of annual earnings.
Yearly Top and Bottom Value
IEX GROUP NV’s stock is valued at €1.75 at 21:40 EST, way under its 52-week high of €2.00 and way above its 52-week low of €1.58.
Volatility
IEX GROUP NV’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.35%, a positive 0.83%, and a positive 6.44%.
IEX GROUP NV’s highest amplitude of average volatility was 4.35% (last week), 5.58% (last month), and 6.44% (last quarter).
Volume
Today’s last reported volume for IEX GROUP NV is 1062 which is 179.47% above its average volume of 380.
Revenue Growth
Year-on-year quarterly revenue growth declined by 5.2%, now sitting on 5M for the twelve trailing months.
More news about IEX GROUP NV.
Stay up to date with our winners and losers daily report
